Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Lydia Scarfò MD

Lydia Scarfò MD

Strategic Research Program on CLL, IRCCS Ospedale San Raffaele; Università Vita Salute San Raffaele, Milano, Italy

Lydia Scarfò received her degree in Medicine and Surgery at the University of Ferrara in 2006, with a specialization in Hematology in 2012 and Internal Medicine in 2017. In 2012, she moved to IRCC Ospedale San Raffaele, Milano, Italy where she is now assistant professor in Internal Medicine at Università Vita-Salute San Raffaele. She is involved in the CLL out-patient clinic (Strategic Research Program on CLL), which is dedicated to the management and treatment of CLL patients, including design and conduct of clinical trials. She is actively participating in both preclinical and clinical studies and currently co-investigator in over 20 clinical trials in CLL and related disorders, including phase 1 studies. Dr. Scarfo is principal investigator in observational studies focusing on quality of life in patients with CLL treated with novel agents and in one interventional trial based on a chemo-free approach in hairy cell leukemia (HCL). She successfully completed the Clinical Research Training in Hematology (CRTH) year 2016-2017, promoted by the European Hematology Association (EHA). Her research activity is focused on management of B cell lymphoproliferative disorders through a better understanding of their pathogenetic mechanisms.


Advisory Board: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly, Merck

Speaker Bureau: OctaPharma

Recent Contributions to PracticeUpdate:

  1. Anti-CD19 CAR T-Cell Therapy for Richter Transformation